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ABSTRACT: Background: Machado-Joseph disease (or
spinocerebellar ataxia type 3) is a late-onset polyglut-
amine neurodegenerative disorder caused by a mutation
in the ATXN3 gene, which encodes for the ubiquitously
expressed protein ataxin-3. Previous studies on cell and
animal models have suggested that mutated ataxin-3 is
involved in transcriptional dysregulation. Starting with a
whole-transcriptome profiling of peripheral blood samples
from patients and controls, we aimed to confirm abnormal
expression profiles in Machado-Joseph disease and to
identify promising up-regulated genes as potential candi-
date biomarkers of disease status.
Methods: The Illumina Human V4-HT12 array was used
to measure transcriptome-wide gene expression in
peripheral blood samples from 12 patients and 12 con-
trols. Technical validation and validation in an independ-
ent set of samples were performed by quantitative real-
time polymerase chain reaction (PCR).
Results: Based on the results from the microarray,
twenty six genes, found to be up-regulated in patients,
were selected for technical validation by quantitative
real-time PCR (validation rate of 81% for the up-
regulation trend). Fourteen of these were further tested
in an independent set of 42 patients and 35 controls;
10 genes maintained the up-regulation trend (FCGR3B,
CSR2RA, CLC, TNFSF14, SLA, P2RY13, FPR2,
SELPLG, YIPF6, and GPR96); FCGR3B, P2RY13, and
SELPLG were significantly up-regulated in patients
when compared with controls.
Conclusions: Our findings support the hypothesis that
mutated ataxin-3 is associated with transcription dysre-
gulation, detectable in peripheral blood cells. Further-
more, this is the first report suggesting a pool of up-
regulated genes in Machado-Joseph disease that may
have the potential to be used for fine phenotyping of
this disease. VC 2015 International Parkinson and Move-
ment Disorder Society
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Machado-Joseph disease (MJD; MIM #109150;
ORPHA98757), also named spinocerebellar ataxia type
3, is the most common autosomal dominant ataxia
worldwide1 and the second most common polyglut-
amine (polyQ) disorder, following Huntington’s disease
(HD).2 Machado-Joseph disease is a clinically heteroge-
neous neurodegenerative disorder with an average onset
around the fourth decade of life.3,4 It is characterized
by a wide range of manifestations, including ataxia,
progressive external ophthalmoplegia, pyramidal and
non-pyramidal signs, dystonia with rigidity, and distal
muscular atrophy.3,4 A widespread neuronal loss in the
cerebellum, pons, medulla oblongata, basal ganglia,
thalamus, midbrain, and cerebral cortex is common in
this disease.5 Effective treatment for MJD is still lack-
ing, and only symptomatic therapeutics are available.6
The MJD gene—ATXN3—mapped to 14q32.1 con-
tains a (CAG)n tract at exon 10, which in mutant allele
is expanded, typically beyond 51 repeat units.7,8 A neg-
ative correlation between the number of CAG repeats
in the expanded allele and the age at onset has been
widely described, with the size of the CAG tract
accounting for nearly 50% to 75% of the variation in
the age at onset.6 The ATXN3 gene encodes for ataxin-
3, a polyQ protein ubiquitously expressed in neuronal
and non-neuronal tissues. Expansions of the polyQ
tract above the pathological threshold initiates a cas-
cade of pathogenic events that are being extensively
studied.9,10 Similarly to MJD, in other polyQ diseases
the expanded repeat triggers conformational changes in
the corresponding proteins, leading to the formation of
intracellular inclusions, considered the hallmark of this
group of disorders.11 In MJD, however, the characteris-
tic neuronal intranuclear inclusions do not seem to be
the main toxic entity (revised in Evers et al.9). Mutated
ataxin-3 seems to be involved in transcriptional regula-
tion via two processes: (1) recruitment of transcription
factors to polyQ-rich inclusions12-14 and (2) altered
interactions with transcription factors and co-activa-
tors.15-19 So far, patterns of transcriptional dysregula-
tion caused by mutated ataxin-3 have been studied only
in cellular and animal models. In such models, tran-
scriptional alterations of genes involved in inflamma-
tory processes, cell signaling, and cell surface–
associated proteins has been described.17,20,21 Studies
of disease-modifying compounds, in the context of clin-
ical trials, have been recently initiated for MJD,22,23 but
gross clinical evaluation alone might not be sensitive
enough to monitor disease progression and detect subtle
therapeutic benefits; this is particularly true in diseases
of slow progression, such as MJD. The development of
disease-related biomarkers is therefore urgently needed.
Gene expression profiling arrays, by identifying disease-
specific transcriptional changes in blood, an easily
accessible tissue, can boost the identification of poten-
tial biomarkers (revised in Coppola and Geschwind24).
These transcriptional changes have not been investi-
gated in MJD patients, and their potential as bio-
markers of disease remains to be evaluated. In this
study we used microarrays to generate gene expression
profiles in peripheral blood samples of MJD
patients, aiming to confirm the presence of altered gene
expression patterns in MJD and to identify up-
regulated genes as potential candidate biomarkers of
disease status.
Methods
Subjects and Sampling
Peripheral blood was collected from MJD Azorean
patients and control individuals. A set of 12 patients
and 12 controls was used for the gene expression
microarray analysis and technical validation (Table 1).
To ensure a homogeneous group of subjects, patients
with an age at onset around the average (40 y) in
our series of cases, and presenting mainly cerebellar
alterations, were selected for this phase of the study.
An independent set of 42 patients and 35 controls was
used for further validation (Table 1). All patients had
a clinical and a molecular diagnosis of MJD (con-
firmed carriers of the ATXN3 mutation). Patients
were recruited through the Department of Neurol-
ogy—Hospital Divino Espırito Santo (HDES, Ponta
Delgada, Azores, Portugal). This study was approved
by the Ethics Committee of the HDES, and all partici-
pants provided written informed consent.
RNA Isolation and Gene Expression
Microarrays
Whole-blood samples were collected in TempusTM
Blood RNA tubes (Applied Biosystems, Waltham,
TABLE 1. Characterization of the studied subjects accord-
ing to biological group and study design
Study Design
Microarray and
Technical Validation
Independent
Set Validation
MJD Patients
N 12 42
Female/male 10/2 26/16
Age (y) 426 6 [34-52] 476 15 [22-82]
Age at onset (y) 346 6 [28-46] 376 13 [12-70]
CAG repeats
Normal allele 206 6 [14-29] 216 5 [14-29]
Expanded allele 726 2 [69-75] 716 4 [62-79]
Disease duration (y) 86 3 [6-17] 106 8 [0-30]
Controls
N 12 35
Female/male 6/6 23/12
Age (y) 376 13 [19-61] 466 12 [24-77]
All quantitative variables were presented as mean6 standard deviation
[range].
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MA, USA), and total RNA was isolated using the
TempusTM Spin RNA Isolation Kit (Applied Biosys-
tems), following the manufacturer’s protocol. The
integrity of total RNA samples was assessed using the
RNA 6000 Nano Kit on a 2100 Bioanalyzer (Agilent
Technologies, Santa Clara, CA, USA).
RNA was amplified, biotin-labeled, and hybridized
on a transcriptome-wide expression Illumina Human
V4-HT12 array. Slides were scanned using Illumina
BeadStation, and the signal was extracted using the
Illumina BeadStudio software. All arrays were per-
formed in the same core facility.
Technical Validation of Candidate
Blood-Based Biomarkers
Up-regulation is more reliably detected than down-
regulation, because it is not dependent on the lower
detection limit of the quantification methods; there-
fore, for the next phases of the study, we ranked and
selected only those genes that in the gene expression
microarray were up-regulated in patients. Up-regulated
genes with a Benjamini-Hochberg false discovery rate
(FDR) adjusted P-value less than 0.05 and a log ratio
greater than 1.2 were ranked. Consistency of the log
ratio between pairs and maximal values of expression
levels were further evaluated as criteria for the ranking
procedure. Twenty-six genes that fulfilled the previ-
ously described criteria were selected for quantitative
real-time polymerase chain reaction (PCR; qPCR) tech-
nical validation, using the same set of samples previ-
ously used in the microarrays.
One microgram of total RNA was used to synthe-
size complementary DNA, using the High Capacity
cDNA Reverse Transcription Kit (Applied Biosystems),
according to the manufacturer’s protocol. The Taq-
Man Gene Expression Master Mix and prevalidated
TaqMan Gene Expression Assays (TaqMan IDs are
described in Table 2) were used for qPCR (Applied
Biosystems). TaqMan gene expression assays were
designed, tested, and optimized to address all Mini-
mum Information for Publication of Quantitative
Real-Time PCR Experiments (MIQE) guidelines.25
More information on these assays is given in the white
paper by Life Technologies (available at: https://tools.
lifetechnologies.com/content/sfs/brochures/cms_088754.
pdf). The PPIB (peptidylpropyl isomerase B;
Hs00168719_m1) gene was used as the reference gene
for qPCR validation. This reference gene is one of the
most stably expressed genes in human blood, suitable
for normalization in qPCR studies.26 Moreover, the
PPIB gene was identified as an appropriated gene for
expression normalization in blood of HD patients and
R6/2 mice.27 Quantitative PCR was performed in a
7900HT Fast Real-Time PCR System (Applied Biosys-
tems). Each sample was run in triplicate alongside
with the reference gene.
Validation in an Independent Set of Samples
From the list of 26 genes subject to the technical vali-
dation, the 14 genes showing a consistent up-regulation
trend in the technical validation phase, with the highest
fold change and/or the lowest P-value, were further
investigated in an independent set of samples (42
patients and 35 controls). The qPCR methodology was
as described previously (Technical Validation of Candi-
date Blood-Based Biomarkers subsection). Gene ontol-
ogy annotations were performed in Qiagen’s interactive
pathways analysis software (QIAGEN Redwood City,
www.qiagen.com/ingenuity).
Statistical Analysis
Raw data obtained from the Illumina Human V4-
HT12 arrays were analyzed with Bioconductor pack-
ages, as previously described.28 Briefly, quality assess-
ment included inter-array Pearson correlation and
clustering based on top variant genes. Raw expression
values were log2 transformed and normalized using
quantiles. Batch effects were corrected using the Com-
Bat algorithm.29 Differential expression analysis
(patients vs. controls) was performed using the limma
package.28 Up-regulated genes were considered for
further analysis when FDR-adjusted P-value was lower
than 0.05, and log ratio was higher than 1.2-fold.
Because controls were hybridized in separate batches,
an increased rate of false positives was expected. To
minimize this issue, we applied a batch-correction
algorithm (see earlier description), adopted a very con-
servative statistical threshold (FDR<0.05), and veri-
fied all selected candidates by qPCR.
In the qPCR validation phases of this study (techni-
cal validation and validation in an independent set of
samples), relative expression values were normalized
to the reference gene (PPIB), and fold change values
were calculated by using the 2-DDCt method.30 A two-
sample, two-tailed Student’s t test was used to com-
pare the DCq (Cq, also named cycle threshold [Ct], is
quantification cycle Cq, as suggested by MIQE guide-
lines25) values between the two biological groups
(patients vs. controls), and a P-value was calculated.
All statistical procedures were performed by using the
DataAssist v3.0 software (Applied Biosystems).
Results
Microarray-based gene expression profiling was
used to analyze global gene expression in peripheral
blood samples of MJD patients and controls. We iden-
tified a total of 5,523 up-regulated probes, whereas
6,232 were down-regulated (FDR adjusted P-val-
ue< 0.05) when comparing patients with controls.
From the 26 top candidate biomarkers (Table 2)
selected for technical validation by qPCR, we con-
firmed an up-regulation trend in 21 of 26 genes
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(validation rate of 81%), although only 10 were statis-
tically significant. From these 21 genes, 14 (Table 2)
were selected for validation by qPCR in an independ-
ent set of MJD patients and controls. Given the fact
that the sex ratio in our first set of MJD samples was
skewed toward females, we choose a 1:1 male to
female ratio in our independent set of samples (both
cases and controls) to ensure that the observed up-
regulation was not caused by a sex effect. In this
phase, a validation rate of 71% was obtained, with 10
of 14 genes showing an up-regulation trend. In the
new set of samples, the expression levels of FCGR3B,
CSF2RA, CLC, FPR2, SLA, GPR97, P2RY13,
TNFSF14, SELPLG, and YIPF6 were 1.11- to 2.60-
fold higher in patients when compared with controls
(Fig. 1; Table 2). Noteworthy, FCGR3B, P2RY13,
TABLE 2. Candidate blood-based transcriptional biomarkers selected for the qPCR technical validation and validation in an
independent set
Microarray Data
Technical
Validation
Independent
Validation
TaqMan ID Gene ID Symbola Full Namea Log Ratiob P-Valuec FCd P-Value FCd P-Value
Transmembrane receptorse
Hs00275547_m1 2215 FCGR3B Fc fragment of IgG, low-affinity IIIb, receptor
(CD16b)
1.943 1.18E-02 4.0582 6.80E-03 2.597 9.20E-03
Hs04191069_gH 3802 KIR2DL1 Killer cell immunoglobulin-like receptor, 2
domains, long cytoplasmic tail, 1
1.767 1.30E-03 1.8267 1.94E-01 Not selected
Hs00427106_m1 3805 KIR2DL4 Killer cell immunoglobulin-like receptor, 2
domains, long cytoplasmic tail, 4
1.396 1.19E-03 1.2968 4.38E-01 Not selected
Hs00538900_m1 1438 CSF2RA Colony-stimulating factor 2 receptor, alpha,
low-affinity (granulocyte-macrophage)
1.294 5.80E-05 1.5071 1.44E-01 1.331 1.37E-01
Enzymes
Hs01055743_m1 1178 CLC Charcot-Leyden crystal protein 1.763 4.91E-03 3.4077 1.70E-02 2.041 1.13E-01
Hs01587865_g1 4051 CYP4F3 Cytochrome P450, family 4, subfamily F,
polypeptide 3
1.512 2.14E-03 4.0785 4.77E-02 0.911 8.01E-01
Hs00193422_m1 3029 HAGH Hydroxyacylglutathione hydrolase 1.368 4.84E-03 0.7296 3.10E-01 Not selected
G-protein coupled receptors
Hs01891184_s1 3579 CXCR2 Chemokine (C-X-C motif) receptor 2 2.040 4.99E-03 1.9372 2.13E-01 Not selected
Hs02759175_s1 2358 FPR2 Formyl peptide receptor 2 1.541 4.56E-03 1.7242 9.79E-02 1.370 2.77E-01
Hs00416889_m1 222487 GPR97 G protein-coupled receptor 97 1.315 8.40E-03 3.3142 7.61E-02 1.107 7.77E-01
Hs03043902_s1 53829 P2RY13 Purinergic receptor P2Y, G-protein coupled,
13
1.313 1.37E-03 2.1724 1.07E-02 1.665 6.20E-03
Peptidases
Hs00153519_m1 4311 MME Membrane metallo-endopeptidase 1.476 4.07E-02 2.1544 1.84E-01 0.994 9.90E-01
Hs01073631_m1 64167 ERAP2 Endoplasmic reticulum aminopeptidase 2 1.410 2.42E-03 0.5328 5.63E-02 Not selected
Cytokines
Hs00542477_m1 8740 TNFSF14 Tumor necrosis factor (ligand) superfamily,
member 14
1.562 4.33E-04 5.6394 3.00E-04 1.687 9.02E-02
Others
Hs00331399_m1 57535 KIAA1324 KIAA1324 2.101 1.77E-04 1.3916 2.65E-01 Not selected
Hs00846590_s1 11026 LILRA3 Leukocyte immunoglobulin-like receptor,
subfamily A (without TM domain), member
3
2.037 2.98E-05 0.5844 5.40E-02 Not selected
Hs00747812_m1 3813 KIR3DS1 Killer cell immunoglobulin-like receptor,
three domains, short cytoplasmic tail, 1
1.993 1.49E-03 1.1759 6.18E-01 Not selected
Hs00962914_m1 7057 THBS1 Thrombospondin 1 1.684 4.68E-05 0.7767 5.77E-01 Not selected
Hs00160066_m1 5266 PI3 Peptidase inhibitor 3, skin-derived 1.628 3.79E-02 3.1875 4.40E-02 0.525 1.74E-01
Hs01066294_m1 23762 OSBP2 Oxysterol binding protein 2 1.471 2.66E-03 0.9111 8.40E-01 Not selected
Hs00190581_m1 8875 VNN2 Vanin 2 1.465 4.46E-03 1.4282 2.87E-01 Not selected
Hs00275682_s1 3310 HSPA6 Heat shock 70kDa protein 6 (HSP70B’) 1.344 1.22E-04 1.2347 3.82E-01 Not selected
Hs00218346_m1 55363 HEMGN Hemogen 1.328 8.09E-03 3.7584 4.84E-02 0.534 8.01E-02
Hs00277129_m1 6503 SLA Src-like-adaptor 1.308 6.37E-05 2.5137 1.60E-03 1.333 1.15E-01
Hs00356602_m1 6404 SELPLG Selectin P ligand 1.251 4.06E-06 1.9473 1.60E-03 1.324 4.04E-02
Hs00397742_m1 286451 YIPF6 Yip1 domain family, member 6 1.248 1.98E-04 2.5564 1.06E-02 1.136 5.17E-01
aOfficial gene symbol and full name provided by HUGO Gene Nomenclature Committee.
bLog ratio5 log2 (Cy3’/Cy5’).
cP-value calculated by Student’s t test and adjusted for multiple comparisons by FDR (false discovery rate) correction.
dFold Change (FC)5geometric mean 2(-DCqpatients)/geometric mean 2(DCqcontrols).
eGene ontology annotations for technical validated genes were performed in Qiagen’s interactive pathways analysis (IPA) software (QIAGEN, Redwood City,
www.qiagen.com/ingenuity).
N O V E L B L O O D - B A S E D B I O M A R K E R S O F M J D / S C A 3
Movement Disorders, Vol. 30, No. 7, 2015 971
and SELPLG genes were significantly up-regulated
(P< 0.05). According to gene ontology functional
annotations, these genes are mostly related to the
immune system response (FCGR3B, CSF2RA, FPR2,
TNFSF14, and SELPLG) and G-protein coupled
receptor signaling (FPR2, GPR97, and P2RY13).
Within the patients group (patients from technical
and independent set validation), our data show a trend
for higher expression levels in patients with shorter
disease duration compared with patients with longer
disease duration, especially for FCGR3B and CLC,
which were statistically significant (Fig. 2). The com-
parison between fold change values in patients
grouped by CAG size in expanded allele failed to pro-
duce significant results (data not shown).
Discussion
In this study, we confirmed that transcriptional dysre-
gulation can be detected in peripheral blood samples of
MJD patients. We report a set of 10 genes—FCGR3B,
CSF2RA, CLC, FPR2, SLA, GPR97, P2RY13,
TNFSF14, SELPLG, and YIPF6—that consistently
show an up-regulation trend in MJD patients when
compared with controls. Three of these genes—
FCGR3B, P2RY13, and SELPLG—were significantly
up-regulated and therefore should be considered in
future studies as biomarkers of disease status. More-
over, the significantly increased levels of FCGR3B and
CLC messenger RNAs (mRNA) observed in early MJD
stages suggests that, even in a nonaffected tissue (such
FIG. 1. Fold change (FC) values for the 10 genes maintaining an up-regulation trend in an independent set of MJD patients versus controls. Error bars
were obtained by the standard error of mean (SEM) difference of the DCq values, and presented as FC 3 (2SEM – 1) as described elsewhere.37 FC51
implies the absence of expression change. 6¼ The difference is statistically significant (two-tailed T test, P-value< 0.05).
FIG. 2. Fold change (FC) values of the 10 genes, previously validated as biomarkers of MJD status, in controls, patients with 9 or fewer years
elapsed since onset (short disease duration), and with more than 9 years elapsed since onset (long disease duration). Disease duration was defined
as the number of years elapsed from reported age at onset to the collection of blood samples for each patient. Error bars were obtained by the
standard error of mean (SEM) difference of the DCq values, and presented as (FC) 3 (2SEM-1) as described elsewhere.30 FC5 1 implies the absence
of expression change. 6¼The difference between each of the grouped patients and controls is statistically significant (P-value< 0.05); * the difference
between each group of patients is statistically significant (P-value< 0.05).
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as blood), a cellular response closer to the disease onset
is activated in the presence of mutated ataxin-3; with
disease progression (specifically more than 10 y after
onset), expression levels of these genes fall to levels
closer to those found in healthy individuals. These find-
ings suggest a potential of the reported genes to monitor
disease stages; further investigation is nevertheless
required. The potential of molecular alterations in the
fine phenotyping of a polyQ disease was shown by
Bjorkqvist and collaborators,31 who observed higher
levels of interleukin 6 in plasma of HD gene carriers, on
average 16 y before the predicted onset of clinical symp-
toms. This study also reported that interleukin 12 and
granulocyte-macrophage colony-stimulating factor lev-
els significantly decreased from early to moderate stages
of the disease.31
To our knowledge, from the above-mentioned genes,
only TNFSF14, CSF2RA, and FPR2 have been previ-
ously associated with neurodegenerative disorders.
TNFSF14 has been associated with amyotrophic lat-
eral sclerosis (ALS),32 and the latter two genes with
Alzheimer’s disease (AD).33,34 TNFS14, which is
known to be expressed in immature dendrocytes, acti-
vated lymphocytes, monocytes, natural killer cells,
motor neurons, and astrocytes, has been shown to be
up-regulated in the spinal cord of ALS patients.35 This
cytokine is known to be important for both innate
and adaptive immune processes, and it also functions
with interferon-g to induce a singular slow apoptotic
death in tumor cells. Soluble TNFSF14 produced by
astrocytes in ALS acts as a death-inducing ligand in
motor neurons.35 The genetic ablation of the tnfsf14
gene (orthologue to human TNFSF14) in an ALS
mouse model has been related to a slow disease pro-
gression as well as an extended life expectancy, sug-
gesting a possible modifier role for this gene.32
CSF2RA encodes the alpha subunit of the heterodi-
meric receptor for colony-stimulating factor 2 (CSF2),
a hematopoietic factor. In recent years, CSF2 has been
shown to be an important neurotrophic factor in the
central nervous system via binding to its receptor.
Both CSF2 and CSF2RA are expressed in neurons
throughout the central nervous system, astrocytes,
ependymal cells, and choroid plexus cells. In AD,
expression of the protein encoded by CSF2RA has
been found to be dysregulated in the hippocampus of
patients.34 No further links to neurodegenerative dis-
eases have been established for this gene.
The formyl peptide receptor 2 (encoded by FPR2) is
a G-protein–coupled receptor (GPCR) of bacterial che-
motactic peptides expressed in B cells, mononuclear
phagocytes, and microglia. In AD models, the interac-
tion between Ab42 and FPR2 is clearly associated
with microglial cell activation. Moreover, a persistent
internalization of Ab42/FPR2 complexes, which cul-
minates in intracellular fibrillar formation and apopto-
tic death of the cells, suggests that FPR2 can be a
possible therapeutic target for AD.33 Other members
of the GPCR superfamily, which in our study includes
two dysregulated genes (P2RY13 and GPR97), have
been previously reported in polyQ-associated neurode-
generation. In MJD models, the involvement of the
adenosine A2a receptor (A2aR), a GPCR subtype, has
been reported.36 Striatal pathological conditions asso-
ciated with mutant ATXN3 overexpression in a
lentiviral-based model can be abolished by inactivation
of A2aR, providing the first evidence that manipula-
tion of a neuromodulation system operated by A2aRs
is effective in controlling the initial cascade of events
triggered by the pathogenic ataxin-3 protein (synapto-
toxicity and gliosis).36 The P2Y5 gene, a member of
the same purinergic receptor family as P2RY13, has
been validated as a candidate biomarker in HD blood
cells.37
FCGR3B and SELPLG genes were significantly up-
regulated in MJD patients. The Fc fragment of immu-
noglobulin G (IgG), low-affinity IIIb, receptor
(FCGR3B) is an Fc gamma receptor (FcgR), which
belong to a family of immunoglobulin-like receptors
that bind to the Fc portion of IgG and mediate the
response of effector cells to immune complexes.38
Activation of these receptors can result in a pro-
inflammatory response including the release of cyto-
kines and other mediators. Evidence concerning the
ligation of specific FcgRs in the central nervous system
by IgG and alternate ligands, which promote neuroin-
flammation or enhance neurodegeneration, were previ-
ously reported.38 Selectin P ligand (SELPLG) gene
encodes a glycoprotein that functions as a high-affinity
counter-receptor for the cell adhesion molecules P-, E-,
and L-selectin expressed on myeloid cells and stimu-
lated T lymphocytes.39 The selectin family mediates
the tethering and rolling of leukocytes on the vascular
wall during the process of leukocyte migration into
the tissues under physiological and pathological condi-
tions.40 The role of selectins in leukocyte–endothelial
interactions in the pathogenesis of neurological dis-
eases had been debated.40 Rodrigues et al.41 reported
that depletion of ATXN3, using small-interference
RNA in human and mouse cells, causes a decrease in
expression of important cell adhesion molecules, indi-
cating that the extracellular matrix–cell or cell–cell
interconnection was compromised.41
Five of the 10 candidate biomarkers identified in the
present study play a role in immune system pathways.
This is not surprising given the cellular source of the
mRNA used in our analysis. Noteworthy, this finding is
in line with previous studies, which have shown that
mutant ataxin-3 mediates up-regulation of several cyto-
kines and cytokine-inducible transcription factors in
cell models and in brain tissue of MJD patients,17,20,42
although none of the previously reported genes were
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up-regulated in our study. Immune system alterations
also have been reported in peripheral blood of HD
patients, inclusively, before the manifestation of motor
symptoms.31,43,44 Globally, genes involved in immune
system and GPCRs may constitute good candidates for
biomarkers in polyQ disorders and should be consid-
ered in future studies of MJD progression.
In summary, our results support the hypothesis that
mutated ataxin-3 is associated with transcription dys-
regulation in peripheral blood cells. Based on the tran-
scriptional profile of MJD patients, this study
identified for the first time a pool of up-regulated
genes in this disease. The understanding of how the
up-regulation of these genes relates to clinical-
associated progressive features during the natural his-
tory of MJD will be crucial in clinical trials measuring
the effectiveness of new drugs.
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